NEW YORK (360Dx) – Emosis, BioRap Technologies, and Rambam MedTech said today that they have entered into an exclusive license agreement to develop and commercialize a microparticle biomarker hypercoagulation kit for several indications.

The license is based on technology developed by researchers at the Rappaport Institute at the Technion-Israel Institute of Technology and Rambam Healthcare Campus, an academic hospital serving more than 2 million residents in northern Israel.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.